Equities research analysts predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post ($0.16) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Infinity Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.14). Infinity Pharmaceuticals posted earnings per share of ($0.12) in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The business is expected to issue its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.73) per share for the current fiscal year, with EPS estimates ranging from ($0.76) to ($0.71). For the next financial year, analysts anticipate that the company will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.87) to ($0.54). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.19). The firm had revenue of $2.14 million for the quarter, compared to analyst estimates of $10.07 million.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its holdings in shares of Infinity Pharmaceuticals by 3.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,101,085 shares of the biotechnology company’s stock worth $1,299,000 after buying an additional 35,211 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Infinity Pharmaceuticals by 8.4% during the first quarter. Renaissance Technologies LLC now owns 891,200 shares of the biotechnology company’s stock worth $1,675,000 after buying an additional 69,300 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Infinity Pharmaceuticals by 12.5% during the first quarter. Acadian Asset Management LLC now owns 542,519 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 60,383 shares in the last quarter. Fosun International Ltd grew its holdings in shares of Infinity Pharmaceuticals by 10.6% during the first quarter. Fosun International Ltd now owns 418,296 shares of the biotechnology company’s stock worth $786,000 after buying an additional 40,000 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Infinity Pharmaceuticals by 48.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 191,927 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 62,800 shares during the period. Institutional investors and hedge funds own 54.33% of the company’s stock.
Shares of NASDAQ INFI traded up $0.05 during midday trading on Friday, reaching $1.64. 714 shares of the stock were exchanged, compared to its average volume of 94,132. The company has a market cap of $93.93 million, a PE ratio of -8.25 and a beta of 1.95. Infinity Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $2.92.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Read More: How to invest in blue-chip stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.